Rockefeller Capital Management
MRNA icon

Rockefeller Capital Management’s Moderna MRNA Stock Holding History

Rockefeller Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Buy
20,783
+205
+1% +$10.6K ﹤0.01% 1523
2026
Q1 		$1.05M Buy
20,578
+1,799
+10% +$83.9K ﹤0.01% 1590
2025
Q4 		$554K Sell
18,779
-908
-5% -$24.7K ﹤0.01% 1848
2025
Q3 		$509K Sell
19,687
-1,674
-8% -$46.7K ﹤0.01% 1757
2025
Q2 		$589K Sell
21,361
-54,235
-72% -$1.43M ﹤0.01% 1513
2025
Q1 		$2.14M Buy
75,596
+7,882
+12% +$280K 0.01% 1012
2024
Q4 		$2.82M Sell
67,714
-491
-0.7% -$23.5K 0.01% 888
2024
Q3 		$4.56M Sell
68,205
-108,516
-61% -$9.96M 0.01% 731
2024
Q2 		$21M Buy
176,721
+2,198
+1% +$278K 0.06% 304
2024
Q1 		$18.6M Buy
174,523
+4,465
+3% +$450K 0.05% 347
2023
Q4 		$16.9M Buy
170,058
+514
+0.3% +$43.2K 0.06% 325
2023
Q3 		$17.5M Buy
169,544
+10,895
+7% +$1.22M 0.07% 291
2023
Q2 		$19.3M Buy
158,649
+38,203
+32% +$5.1M 0.07% 277
2023
Q1 		$18.5M Buy
120,446
+1,962
+2% +$324K 0.08% 278
2022
Q4 		$21.3M Buy
118,484
+76,551
+183% +$12.5M 0.11% 213
2022
Q3 		$4.96M Buy
41,933
+4,000
+11% +$607K 0.03% 534
2022
Q2 		$5.42M Buy
37,933
+1,922
+5% +$275K 0.03% 500
2022
Q1 		$6.2M Buy
36,011
+12,222
+51% +$2.06M 0.03% 497
2021
Q4 		$6.04M Buy
23,789
+1,305
+6% +$382K 0.03% 488
2021
Q3 		$8.65M Buy
22,484
+3,043
+16% +$1.12M 0.05% 342
2021
Q2 		$4.57M Sell
19,441
-3,518
-15% -$629K 0.03% 475
2021
Q1 		$3.01M Buy
22,959
+1,810
+9% +$262K 0.02% 476
2020
Q4 		$2.21M Sell
21,149
-4,775
-18% -$483K 0.02% 499
2020
Q3 		$1.83M Sell
25,924
-4,138
-14% -$289K 0.02% 453
2020
Q2 		$1.93M Sell
30,062
-14,220
-32% -$779K 0.02% 397
2020
Q1 		$1.33M Buy
44,282
+44,100
+24,231% +$1.01M 0.02% 417
2019
Q4 		$4K Buy
182
+82
+82% +$1.46K ﹤0.01% 1824
2019
Q3 		$2K Buy
+100
New +$1.48K ﹤0.01% 1790

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Rockefeller Capital Management's MRNA Position: Q2 2026 in Review

Rockefeller Capital Management increased its Moderna (MRNA) stake by 1% in Q2 2026, buying an estimated $10.6K and bringing the position to 20,783 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1523.

Rockefeller Capital Management first reported a position in MRNA in Q3 2019 and has held it in 28 quarters since. The position peaked at $21.3M in Q4 2022. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Rockefeller Capital Management held 20,783 shares of Moderna worth $1.46M as of Q2 2026.
  • Rockefeller Capital Management bought 205 Moderna shares in Q2 2026, an estimated $10.6K.
  • Moderna made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1523 holding.
  • Rockefeller Capital Management first reported a position in Moderna in Q3 2019 and has held it in 28 quarters since.
  • Rockefeller Capital Management's Moderna position peaked at $21.3M in Q4 2022.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.